In this episode, David Flores sits down with Donald Currie, the Clinical Director for Dimensions Retreats in Algonquin Highlands. He joins us alongside world-renowned cultural anthropologist, ethnobotanist, author, and photographer Wade Davis to discuss the launch of Dimensions’ new Zen Plus program which has its sight on taking the world of psychedelic retreat centers to a whole new level.
Similar Posts
How to Legally Access Psychedelic Therapy in Canada | The Psychedelic Investor
How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA.
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult.
In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy.
There is also a new avenue called the Health Canada “Special Access Program”, though relatively few people have gone through that route so far.
In the interview, we also discuss David’s company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves.
Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!
Psychedelic Business Roundup- Is California Next For Legalizing Psychedelics?
April 26, 2021- This week’s Psychedelic Business News Round Up’s…
Interview With Joshua Bartch
Mydecine Innovations Group’s Director, CEO & Co-Founder, Joshua Bartch chats with our Director of Content, Jill Ettinger.
Atma Journey Centers Opens First Clinic In Calgary, Alberta
In this episode, we chat with David Harder, the Co-Founder and CEO of ATMA Journey Centers, about their new healing and training space.
Interview With Michelle Janikian, Author, Host & Editor at Psychedelics Today
Michelle opens up about how her work as a cannabis writer led her down the path of psychedelics, her interest in safe magic mushroom use and why she was compelled to write her guidebook Your Psilocybin Mushroom Companion.
MAPS Phase 3 MDMA To Treat PTSD Trial Results: WOW [GREAT News For NUMI, MindMed, MYCO & Atai ]
MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.
Also, there were 0 cases of serious adverse side effects in the MDMA group.
So which companies will be the largest benefactors of these results?
Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently
2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.
3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.
4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.
5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.
Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #NUMIStock